Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 3, 1998, Pages 339-346

  Bowen, James D ^a   Petersdorf, Stephen H ^a   Richards, Todd L ^a   Maravilla, Ken R ^a   Dale, David C ^a   Price, Tom H ^a   St John, Tom P ^a   Yu, Albert S ^a  

^a Box 356465 ^*

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; CD18 ANTIGEN; MONOCLONAL ANTIBODY; ROVELIZUMAB; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GINGIVITIS; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE MIGRATION; LEUKOCYTOSIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN INFLAMMATION; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; ANTIGENS, CD18; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTES; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031684546     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90183-7     Document Type: Article

References (15)

1. Martin R, McFarland H, McFarlin D. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-87.
2. Springer T. Adhesion receptors of the immune system. Nature 1990;346:425-34.
3. Arnaout M. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990;75: 1037-50.
4. Arnaout M. Leukocyte adhesion molecules deficiency: its structural basis, pathophysiology and implications for modulating the inflammatory response. Immunol Rev 1990;114:145-80.
5. Mazzone A, Ricevuti G. Leukocyte CD11/CD18 integrins: biological and clinical relevance. Haematologica 1995;80:161-75.
6. Baume D, Kuentz M, Pico J, Beaujean F, Cordonnier C, Vernant JP, et al. Failure of a CD18/anti-LFA1 monoclonal antibody infusion to prevent graft rejection in leukemic patients receiving T-depleted allogeneic bone marrow transplantation. Transplantation 1989; 47:472-4.
7. Cannella B, Cross A, Raine C. Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis (EAE). J Neuroimmunol 1993;46:43-55.
8. Welsh C, Rose J, Hill K, Townsend J. Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 alpha. J Neuroimmunol 1993;43:161-7.
9. Huitinga I, Damoiseauz J, Dopp E, Kijkstra C. Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats. Eur J Immunol 1993;23:709-15.
10. Rose LM, Richards TL, Peterson J, Petersen R, Alvord EC Jr. Resolution of CNS lesions following treatment of experimental allergic encephalomyelitis in macaques with monoclonal antibody to the CD18 leukocyte integrin. Mult Scler 1997;2:259-66.
11. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-31.
12. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
13. Sipe J, Knobler R, Braheny S, Rice G, Panitch H, Oldstone M. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-72.
14. Perillie P, Finch S. Quantitative studies of the local exudative cellular reaction in acute leukemia. J Clin Invest 1964;43:425-30.
15. Rocci ML Jr, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983;16:203-16.